Plerixafor use in poor mobilizer patients for autologous transplant. Uso del plerixafor en pacientes pobres movilizadores para trasplante autólogo.

Abstract

Autologous transplantation is the standard treatment for patients with multiple myeloma or intermediate or high grade nonHodgkin’s lymphoma with chemosensitive relapses, which allows patients to recover after receiving chemotherapy at ablative doses. In Colombia, in 2012, 1 per 100 million inhabitants were made (435 patients among autologous and aloal), being a country with low average transplants per person. Objective: To describe the clinical characteristics and the triggers of poor mobilizing patients in a transplant at the Imbanaco Medical Center in Cali and in which paragraphs were received for a second mobilization attempt or to perform the allogeneic transplant. Materials and methods: A retrospective descriptive study based on the medical records of the Imbanaco Medical Center of Cali, from 2004 to 2015. Age, sex, number of apheresis, delay, collection and recovery were taken into account. Results: 207 autologous transplants were performed, 196 in adults and 11 in children. Within adults, 5 patients (2.55%) were classified as poor mobilizers, and of these, 4 were remobilized with plerixa for more G-CSF and 11 aphereses were made in the 4 patients. All the patients were taken to an autologous transplant that received conventional conditioning, BEAM for lymphomas and melfalan for the patient with multiple myeloma. All the patients left aplasia, on average at 14.25 days (range 13 to 15). Conclusions: plerixafor allows mobilization and collection of hematopoietic progenitors in patients ‘poor mobilizers’, and can be transplanted. The delay in administrative procedures endangers the lives of patients.